

Caisson Biotech Wins Innovation Recognition Award

Oklahoma City, OK – April 8, 2015 – Caisson Biotech, Inc. (Caisson) an Emergent Technologies company, was presented today with the Innovation Recognition Award from the Oklahoma Bioscience Association for its outstanding contributions and accomplishments to the biosciences industry in Oklahoma and around the world.

Caisson has developed an innovative drug delivery system, HEPTune[®], that uses a naturally occurring sugar polymer (heparosan) to conjugate, coat or complex to a drug. Advantages of HEPTune drug delivery include its inertness, its ability to not trigger an immune system response, its biocompatibility, and its flexibility. The HEPTune technology has the promise to improve patient care, drug safety and drug performance.

Caisson Biotech, Haus Bioceuticals, and Moleculera Labs were finalists for the Innovation Recognition Award. The Oklahoma Bioscience Association cited two key reasons Caisson was selected as the winner of the award; 1) the current and potential commercial success of the Caisson drug delivery technology and 2) the many benefits it could provide patients across a multitude of indications.

“We greatly appreciate the honor of winning the Innovation Recognition Award and the continued support we receive from the State of Oklahoma,” said Thomas Harlan, Caisson’s CEO. “Organizations such as the Oklahoma Bioscience Association have been instrumental in the growth of biotech and the subsequent economic development and technological innovations now benefitting the State of Oklahoma and the rest of the world.”

About Caisson Biotech, L.L.C.

Caisson Biotech is a subsidiary of Heparinex, L.L.C. Caisson brings uniqueness to the drug delivery market with its approach of using heparosan to conjugate, coat or complex to a drug. This novel drug delivery platform was developed by Chief Scientist and Professor Dr. Paul L. DeAngelis at the University of Oklahoma Health Sciences Center. To learn more about Caisson, visit www.caissonbiotech.com.

Caisson is funded and managed by Emergent Technologies, Inc. a leading life sciences technology investment and management firm.

About Emergent Technologies, Inc.

Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) is a leading innovation solutions company that identifies, manages, develops and partners to turn game-changing scientific discoveries into market-driven products. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of

promising ideas and underutilized intellectual properties without the risk associated with commercial development. The company applies its experience and expertise to provide investors, entrepreneurs, start-up companies and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit: www.emergenttechnologies.com.

###

Media Contact:

Cameron Mackie
Emergent Technologies, Inc.
Phone: 512-697-8224
cmackie@etibio.com